Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults

Clinical and Vaccine Immunology, 04/27/2012

Low–dose MF59–adjuvanted influenza vaccine, even with 3.75µg hemagglutinin antigen, might induce excellent long–term immunity that is comparable to the conventional dose of unadjuvanted vaccine among healthy adults aged 18 to 64 years.

Print Article Summary Cat 2 CME Report